Mesothelioma Treatment Costs

Mesothelioma Treatment Costs

Mesothelioma Treatment Costs
Category	Estimated Cost
Total Lifetime Cost	$400,000–$1,000,000+
EPP Surgery	~$62,408
P/D Surgery	~$53,993
Chemotherapy (6 cycles)	$38,779–$87,741
Immunotherapy (total course)	$292,319
Radiation (per course)	$7,500–$11,100
Mean Hospitalization	$24,901
Trust Fund Recovery	$100,000–$400,000+
Data Year	2014–2024

Overview

Mesothelioma treatment costs are among the highest of any cancer diagnosis, with total lifetime expenses frequently exceeding $400,000 and reaching $1 million or more when surgery, chemotherapy, immunotherapy, diagnostics, hospitalizations, and supportive care are combined. A 2019 analysis of national hospital discharge data found the mean cost per mesothelioma hospitalization was $24,901 in 2014, with surgical cases averaging $29,344 per episode compared to $10,263 for non-surgical hospitalizations.

The financial landscape shifted substantially in October 2020 when the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for unresectable malignant pleural mesothelioma. A cost-effectiveness analysis found the total healthcare cost for Opdivo plus Yervoy was $292,319 over the treatment course, compared to $95,715 for chemotherapy alone — an incremental cost-effectiveness ratio (ICER) of $372,414 per quality-adjusted life year (QALY).

Beyond direct medical expenses, mesothelioma patients and their families face significant indirect costs including lost wages, caregiver burden, travel to specialized treatment centers, and the psychological toll of financial distress. Research shows cancer patients are 2.65 times more likely to file for bankruptcy than people without cancer, and those who do experience a 79% greater mortality risk. However, multiple financial assistance pathways exist, including more than $30 billion in asbestos trust fund assets, litigation compensation, VA disability benefits, and insurance protections for clinical trial participation.

Key Facts

Fact	Detail
Total lifetime treatment cost ranges from $400,000 to over $1 million when multimodal treatments are combined
Mean cost per mesothelioma hospitalization was $24,901 based on 1,675 hospital discharges in 2014
Extrapleural pneumonectomy (EPP) averages $62,408 per procedure (2014 dollars)
Pemetrexed plus cisplatin chemotherapy costs $38,779 for 6 cycles at wholesale acquisition cost
Nivolumab plus ipilimumab immunotherapy totals $292,319 over the treatment course
Cancer patients are 2.65 times more likely to file for bankruptcy than non-cancer patients
Treatment costs vary by region — Northeast hospitalizations average $33,396 vs. $18,206 in the Midwest
Medicare Part D now caps out-of-pocket prescription costs at $2,000 per year under the Inflation Reduction Act
Medicare covers hospice care with no deductible and copays of up to $5 per prescription
Over $30 billion in asbestos trust fund assets remain available for mesothelioma patients
Less than 5% of pleural mesothelioma patients participate in clinical trials, which may cover drug costs
Approximately 35% of cancer caregivers report stopping work due to caregiving demands

Surgical Costs

Surgery remains the most aggressive and most costly single-procedure treatment for mesothelioma. A 2019 peer-reviewed analysis of the National Inpatient Sample (NIS/HCUP) found substantial variation in costs by procedure type.

Procedure	Mean Cost (2014 USD)	Mean Length of Stay
Extrapleural Pneumonectomy (EPP)	$62,408 (95% CI: $48,385–$76,431)	11.2 days
Pleurectomy Decortication (P/D)	$53,993 (95% CI: $43,092–$64,893)	12.6 days
Thoracoscopic Decortication	$46,873	Varies
Thoracoscopic Pleural Biopsy	$16,575 (95% CI: $14,361–$18,790)	5.4 days
Drainage of Pleural Cavity	$16,089	Varies

For peritoneal mesothelioma, cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is the standard surgical approach. A community hospital cost analysis found the average CRS/HIPEC hospital cost was $38,369, with costs largely driven by operative complexity, complications, and length of stay. These surgical figures represent hospital charges only and exclude surgeon fees, anesthesia, post-operative rehabilitation, and extended stays, which can add thousands of dollars per inpatient day.

Chemotherapy Costs

Chemotherapy is the most universally applied mesothelioma treatment, used as standalone therapy or combined with surgery and radiation as part of a multimodal approach. The standard first-line regimen combines pemetrexed (Alimta) with cisplatin or carboplatin.

Regimen	Drug Cost (6 Cycles, 2017 WAC)
Pemetrexed + Cisplatin	$38,779
Pemetrexed + Cisplatin + Bevacizumab	$87,741
Cisplatin alone	~$306
Pemetrexed alone	~$38,437

These figures represent wholesale acquisition costs (WAC) for drugs only and exclude facility fees, administration costs, and toxicity management. Pemetrexed generic availability since 2022 has reduced per-cycle costs from the original WAC figures, though total treatment expenses remain substantial. When bevacizumab is added — commonly recommended for patients ineligible for surgery — total chemotherapy drug costs more than double.

Supportive medications add further expense. Pegfilgrastim (Neulasta and biosimilars) for white blood cell support currently ranges from approximately $240 to $1,742 per injection depending on product, with the average market price around $1,742 as of 2024 — a significant decrease from pre-biosimilar pricing due to competitive market entry.

Immunotherapy Costs

The 2020 FDA approval of nivolumab plus ipilimumab (Opdivo + Yervoy) as first-line treatment for unresectable malignant pleural mesothelioma marked a major advancement in mesothelioma care — and a significant cost escalation.

A 2022 cost-effectiveness study modeled total healthcare costs at $292,319 for Opdivo plus Yervoy over the full treatment course (median treatment duration approximately 18 months), compared to $95,715 for chemotherapy alone. The annual wholesale acquisition cost for nivolumab alone is approximately $198,500, with the full combination regimen exceeding $250,000 annually during active treatment.

The ICER of $372,414 per QALY gained exceeds the standard U.S. willingness-to-pay threshold of $100,000–$200,000 per QALY, meaning immunotherapy for mesothelioma is not considered cost-effective by conventional measures — though it remains the standard of care given demonstrated survival benefits in the CheckMate 743 trial.

Radiation Therapy Costs

Radiation therapy is rarely used alone for mesothelioma but frequently supplements surgery and chemotherapy as part of a multimodal treatment plan. A SEER-Medicare analysis of over 55,000 patients found the median radiation therapy cost for lung cancer was $9,000 per course (IQR $7,500–$11,100) in 2009 dollars.

Notably, factors unrelated to the patient — including practice type, geographic location, and provider — accounted for 43% of variation in lung cancer radiation costs, highlighting significant pricing inconsistency across treatment facilities. Adjusted for inflation to 2025 dollars, the typical radiation therapy course for mesothelioma falls in the range of $12,500 to $15,500.

Diagnostic Procedure Costs

Accurate diagnosis and staging of mesothelioma typically requires multiple imaging studies and invasive biopsies before treatment begins. Thoracoscopic pleural biopsy — often necessary to confirm a mesothelioma diagnosis — averages $16,575 (95% CI: $14,361–$18,790) with a mean hospital stay of 5.4 days.

PET/CT scans for cancer staging range from approximately $1,300 to $4,600 without insurance, with a national average around $4,637 based on healthcare cost database analysis. Medicare copays for outpatient PET scans are substantially lower, typically $63 to $308. Total initial diagnosis and staging costs frequently reach $7,000 to $20,000 before any treatment begins.

Experimental and Emerging Treatment Costs

Several emerging therapies are being investigated for mesothelioma, each carrying substantial cost implications.

Tumor Treating Fields (TTFields): The FDA-approved Optune Lua device costs approximately $21,000 per month based on manufacturer pricing. A cost-effectiveness study found TTFields added an average of $59,663 in lifetime costs compared to standard therapy, with a more favorable ICER of $89,808 per QALY — the only mesothelioma treatment that falls near conventional cost-effectiveness thresholds.

CAR-T Cell Therapy: Chimeric antigen receptor T-cell therapy targeting mesothelin is being investigated in clinical trials for mesothelioma. Approved CAR-T products for other cancers cost $300,000 to $475,000 per infusion, with total treatment costs often exceeding $500,000 when hospitalization and adverse event management are included. Mesothelioma-specific CAR-T therapy remains available only through clinical trials, where sponsors typically cover experimental drug costs.

Gene Therapy: Gene therapy approaches using viral vectors and CRISPR technology remain in early-stage clinical development for mesothelioma. While costs are not yet established, approved gene therapies for other cancers typically cost in the hundreds of thousands of dollars.

Geographic Cost Variation

Mesothelioma treatment costs vary dramatically by U.S. region. An analysis of 1,675 hospital discharges found mean hospitalization costs ranging from $18,206 in the Midwest to $33,396 in the Northeast — a difference of 83%.

U.S. Region	Mean Cost per Hospitalization (2014)	95% Confidence Interval
Northeast	$33,396	$23,045–$43,748
West	$24,967	$19,279–$30,655
South	$21,084	$16,161–$26,006
Midwest	$18,206	$15,523–$20,888

These variations reflect differences in hospital pricing structures, cost of living, and treatment intensity across regions. The Northeast, home to several major mesothelioma treatment centers, tends to perform more complex surgical interventions that drive higher per-episode costs.

International Cost Comparison

U.S. mesothelioma treatment costs are substantially higher than those in other developed nations. A comprehensive review found that chemotherapy drug costs alone in the United States ($38,779 for pemetrexed plus cisplatin) exceed the total lifetime treatment expenditures reported in some countries.

Country	Average Cost	Measurement
United States	$24,901	Per hospitalization (2014)
Italy	~€67,000	Overall per case (2002–2015)
France	€33,422	Annual per patient (2010)
Australia	~$20,573	Lifetime (USD equivalent)
Taiwan	$14,900–$19,598	Lifetime (1997–2005)

The U.S. hospitalization cost of $24,901 reflects only inpatient charges for a single episode, while many international figures represent broader cost metrics. When surgery, chemotherapy, immunotherapy, and supportive care are combined, total U.S. treatment costs are several times higher than reported in most other countries.

Insurance Coverage and Out-of-Pocket Costs

Even with comprehensive health insurance, mesothelioma patients face significant financial exposure. The Kaiser Family Foundation's 2024 Employer Health Benefits Survey found the average single-coverage deductible is $1,787, with 32% of workers facing deductibles of $2,000 or more.

Medicare beneficiaries received important relief through the Inflation Reduction Act, which established a $2,000 annual out-of-pocket cap for Medicare Part D prescription drug costs beginning in 2025. This is particularly significant for mesothelioma patients taking oral medications as part of their treatment regimen.

Medicare covers hospice care — available to patients with a prognosis of six months or less — with no deductible. Copays are limited to up to $5 per prescription for pain and symptom management drugs, and 5% coinsurance for inpatient respite care. Under the Affordable Care Act, health insurance companies cannot deny coverage for participation in clinical trials or limit coverage of routine care costs for enrolled patients.

Financial Toxicity

Financial toxicity — the measurable negative impact of cancer treatment costs on patient well-being — has emerged as a significant concern in oncology research. The National Cancer Institute reports that cancer patients face a 2.65-times greater likelihood of filing for bankruptcy compared to people without cancer, based on a landmark study of Washington State residents.

More alarmingly, cancer patients who file for bankruptcy experience a 79% greater mortality risk than those who do not, suggesting that financial distress itself contributes to poorer health outcomes through mechanisms including treatment non-adherence, delayed care, and psychological stress. Research estimates that 28–48% of cancer survivors experience some degree of financial toxicity.

The financial burden extends to caregivers as well. A 2023 study published in JCO Oncology Practice found that approximately 35% of cancer caregivers stopped working due to caregiving demands, and 30% experienced increased household debt. In households with income below $75,000, cancer caregivers were 18.8 percentage points more likely to stop working than non-cancer caregivers.

Financial Assistance Programs

Multiple financial assistance pathways exist for mesothelioma patients seeking to offset the extraordinary costs of treatment.

Asbestos Trust Funds: More than 60 active asbestos trust funds hold combined assets exceeding $30 billion, established by companies that filed for bankruptcy due to asbestos liability under Section 524(g) of the U.S. Bankruptcy Code. Mesothelioma patients typically recover $100,000 to $400,000 in combined trust fund payments across 15 to 25 qualifying trusts. No lawsuit is required to file trust fund claims.

Litigation: Personal injury lawsuits and wrongful death claims against solvent asbestos defendants can yield settlements and verdicts often exceeding $1 million. Trust fund claims and litigation can be pursued simultaneously.

VA Benefits: Military veterans with mesothelioma from service-related asbestos exposure can pursue VA disability compensation, healthcare through the VA medical system, and Aid and Attendance benefits concurrently with other compensation sources.

Social Security Disability: Mesothelioma qualifies for expedited SSDI processing under the Social Security Administration's Compassionate Allowances program, providing income support typically within weeks rather than months.

Manufacturer Programs: Pharmaceutical manufacturers including Novocure (TTFields) and Bristol Myers Squibb (Opdivo) offer patient assistance programs that may reduce out-of-pocket costs for qualifying patients.

Clinical Trial Participation

Clinical trials offer mesothelioma patients access to cutting-edge treatments while potentially reducing drug costs, since trial sponsors typically cover the cost of investigational agents. However, participation rates remain critically low — less than 5% of pleural mesothelioma patients and less than 2% of non-pleural patients enroll in clinical trials.

The overall national cancer clinical trial participation rate is 7.1%, rising to 21.6% at NCI-designated comprehensive cancer centers. Travel burden is a significant barrier, with nearly 38% of the U.S. population over age 35 living more than 50 miles from an NCI-funded treatment site. Given the concentration of mesothelioma expertise at approximately 20 specialized centers nationwide, travel challenges may be even more pronounced for mesothelioma patients.

Frequently Asked Questions

How much does mesothelioma treatment cost in total?

Total lifetime mesothelioma treatment costs typically range from $400,000 to over $1 million when surgery, chemotherapy, immunotherapy, radiation, diagnostics, hospitalizations, and supportive care are combined. The mean cost per mesothelioma hospitalization alone is $24,901, and patients typically require multiple hospitalizations over the course of treatment. Costs vary significantly based on treatment approach, geographic location, and insurance coverage.

What is the most expensive mesothelioma treatment?

Immunotherapy with nivolumab plus ipilimumab (Opdivo + Yervoy) is currently the most expensive standard mesothelioma treatment, with total treatment course costs of $292,319. Experimental CAR-T cell therapy, if approved for mesothelioma, could exceed $500,000 per treatment course based on pricing of approved CAR-T products for other cancers.

Does insurance cover mesothelioma treatment?

Most health insurance plans, including employer-sponsored insurance, Medicare, and Medicaid, cover standard mesothelioma treatments. However, patients face significant out-of-pocket costs through deductibles, copays, and coinsurance. The average employer-plan deductible is $1,787 per year. Medicare covers hospice care with no deductible. The Inflation Reduction Act caps Medicare Part D out-of-pocket prescription costs at $2,000 per year beginning in 2025.

How can mesothelioma patients get financial help?

Mesothelioma patients can access multiple compensation sources including asbestos trust funds ($100,000–$400,000+ in combined payments), personal injury lawsuits, VA disability benefits, Social Security Disability Insurance through the Compassionate Allowances program, and pharmaceutical manufacturer assistance programs. An experienced mesothelioma attorney can pursue multiple sources simultaneously to maximize compensation.

Does Medicare cover mesothelioma treatment?

Medicare covers mesothelioma treatment under Parts A (inpatient), B (outpatient/physician), and D (prescriptions). Part B typically requires a 20% coinsurance after the deductible is met. Medicare also covers routine costs associated with qualifying clinical trial participation. Hospice care under Medicare has no deductible, with copays limited to $5 per prescription for symptom management drugs.

What is financial toxicity?

Financial toxicity refers to the measurable negative impact of cancer treatment costs on patient well-being and health outcomes. Cancer patients are 2.65 times more likely to file for bankruptcy than non-cancer patients, and those who do face a 79% greater mortality risk. Between 28% and 48% of cancer survivors experience financial toxicity. Mesothelioma patients may face particular vulnerability given the high treatment costs and the fact that most patients are diagnosed at age 72 or older, near or past retirement age.

Can clinical trials reduce mesothelioma treatment costs?

Yes. Clinical trial sponsors typically cover the cost of investigational drugs and treatments. Insurance companies are required under the Affordable Care Act to cover routine care costs during clinical trial participation. However, patients may still face travel and lodging expenses, as mesothelioma clinical trials are concentrated at specialized cancer centers. Less than 5% of mesothelioma patients currently participate in clinical trials.

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Related Pages

• Treatment Options — Overview of all mesothelioma treatment modalities
• Mesothelioma Treatment Centers — Specialized treatment facilities
• Asbestos Trust Funds — Comprehensive trust fund information
• Mesothelioma Lawsuits — Litigation options and compensation
• Mesothelioma Settlements — Settlement values and process
• Mesothelioma Treatment Costs Quick Reference — Quick-reference cost summary
• Veterans Benefits Guide — VA benefits for mesothelioma veterans
• Clinical Trials — Current mesothelioma clinical trials